APA

Ieko M., Yoshida M., Naito S., Nakabayashi T., Kanazawa K., Mizukami K., Mukai M., Atsumi T. & Koike T. (20100927). Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. : International journal of hematology.

Chicago

Ieko Masahiro, Yoshida Mika, Naito Sumiyoshi, Nakabayashi Toru, Kanazawa Kaoru, Mizukami Kazuhiro, Mukai Masaya, Atsumi Tatsuya and Koike Takao. 20100927. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. : International journal of hematology.

Harvard

Ieko M., Yoshida M., Naito S., Nakabayashi T., Kanazawa K., Mizukami K., Mukai M., Atsumi T. and Koike T. (20100927). Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. : International journal of hematology.

MLA

Ieko Masahiro, Yoshida Mika, Naito Sumiyoshi, Nakabayashi Toru, Kanazawa Kaoru, Mizukami Kazuhiro, Mukai Masaya, Atsumi Tatsuya and Koike Takao. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. : International journal of hematology. 20100927.